WO2019012513A1 - Composition cosmétique comprenant coleus forskohlii et cassia occidentalis et/ou cassia alata, et compositions destinées à être utilisées dans le traitement du vitiligo - Google Patents

Composition cosmétique comprenant coleus forskohlii et cassia occidentalis et/ou cassia alata, et compositions destinées à être utilisées dans le traitement du vitiligo Download PDF

Info

Publication number
WO2019012513A1
WO2019012513A1 PCT/IB2018/055248 IB2018055248W WO2019012513A1 WO 2019012513 A1 WO2019012513 A1 WO 2019012513A1 IB 2018055248 W IB2018055248 W IB 2018055248W WO 2019012513 A1 WO2019012513 A1 WO 2019012513A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
topical composition
cassia
composition according
skin
Prior art date
Application number
PCT/IB2018/055248
Other languages
English (en)
Inventor
Silvia Chami De Diehl
Christian Diehl
Original Assignee
Life Science Investments Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Science Investments Ltd filed Critical Life Science Investments Ltd
Priority to JP2020523837A priority Critical patent/JP2020527604A/ja
Priority to US16/630,904 priority patent/US20200155634A1/en
Priority to EP18750507.8A priority patent/EP3651861A1/fr
Publication of WO2019012513A1 publication Critical patent/WO2019012513A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482—Cassia, e.g. golden shower tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/062—Oil-in-water emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/04—Preparations for care of the skin for chemically tanning the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair

Definitions

  • the present invention relates to a cosmeceutical composition comprising plant extracts.
  • the invention further relates to such a composition for therapeutic or non- therapeutic use to treat dermatological infections related to a depigmentation phenomenon and/or canities.
  • the composition according to the invention is also used as a tanning composition.
  • the skin has epidermal units that are responsible for melanin production and distribution, a process called melanogenesis. These units, named epidermal melanin unit (EMU) are composed of a melanocyte surrounded by keratinocytes and regulated by a closed paracrine system. Melanin is the primary determinant of skin, hair, and eye colour. Besides defining an important human phenotypic trait, it has a critical role in photoprotection due to its ability to absorb ultraviolet radiation (UV). Constitutive pigmentation reflects the genetically determined level of melanin and can be changed by several regulatory factors. These factors may be intrinsic (released by keratinocytes and fibroblasts, endocrine, inflammatory and neuronal cells) or extrinsic (UV and drugs).
  • EMU epidermal melanin unit
  • Melanogenesis is a complex process with different stages. When disturbed, it may determine different types of pigmentation defects, which are classified as hyperpigmentation or hypopigmentation (or depigmentation) and which may occur with or without an altered number of melanocytes.
  • hyperpigmentation or hypopigmentation or depigmentation
  • melanogenesis helps to explain the pigmentation defects observed in hypopigmentation or hyperpigmentation, notably in diseases as pytiriasis or vitiligo, and allows the development of potential therapeutic strategies.
  • Melanocytes are specific cells located at the bottom layer of the epidermis. They produce the melanin, namely the skin pigment, through the biochemical pathway of melanogenesis.
  • melanocytes reside in the basal layer of epidermis where they form the EMU.
  • the ratio of melanocytes to keratinocytes is 1 : 10 in the epidermal basal layer of the epidermis.
  • melanoblasts In the hairy region of mammalian skin, melanoblasts (precursor cells of a melanocytes) further enter the newly developing hair follicles where they finally become localized. Once in the hair follicles, melanoblasts are segregated into two populations: one consists of hair matrix melanocytes, which are responsible for pigmentation of the initial hairs; the other population consists of melanocyte stem cells, which are localized at the lower permanent portion of the hair follicle (the bulge region) and are responsible for the maintenance of the hair follicle pigmentary system in the subsequent hair cycles. In non-hairy regions of the human skin, melanoblasts stay immature and reside on the basement membrane of the epidermis where they undergo terminal differentiation into mature melanocytes upon stimulation from keratinocytes.
  • Follicular pigmentation is a result of structural and functional interactions between follicular melanocytes, matrix keratinocytes and dermal papilla fibroblasts.
  • This tripartite system is described as the hair melanin unit or follicular melanin unit.
  • the process of hair pigmentation includes the melanogenic activity of follicular melanocytes, the transfer of melanin granules into keratinocytes and the formation of pigmented hair shafts. It is considered that a transport of melanin granules to keratinocytes in the growing hair shaft is similar to the epidermal phagocytosis of melanosomes mediated by receptor PAR2 on keratinocytes.
  • a-melanocyte-stimulating hormone a-melanocyte-stimulating hormone
  • M1R Melanocortin-1 receptor
  • PKA cytoplasmic protein kinase A
  • the melanogenic effects of a-MSH can be advantageously mimicked by compounds stimulating the cAMP pathway in melanocytes.
  • melanin Two types of melanin are produced by human melanocytes: eumelanin (black) and phaeomelanin (yellow/reddish), their balance depending on individual genetic predispositions and provide the phototype of the skin or of the hair color.
  • tyrosinase carries out tyrosine hydroxylation to L-3,4-dihydroxyphenylalanine (DOPA) which is rapidly oxidized to DOPAquinone.
  • DOPA L-3,4-dihydroxyphenylalanine
  • cysteine DOPAquinone reacts with it, yielding 3- or 5-cysteinylDOPAs, which then oxidize and polymerize, giving rise to yellow-red soluble melanin phaeomelanin-.
  • thiols cysteine, glutathione or thioredoxin
  • brown-black eumelanin is produced.
  • DOPAquinone spontaneously undergoes cyclization to DOPAchrome.
  • DOPAchrome spontaneously loses carboxylic acid and generates 5,6-dihydroxyindole (DHI), which rapidly oxidizes and polymerizes to form dark brown-black, insoluble DHI-melanin.
  • DOPAchrome tautomerase TYRP2/DCT
  • DOPAchrome will form DHI-2-carboxylic acid (DHICA).
  • DHICA DHI-2-carboxylic acid
  • Tyrosinase and TYRP1 catalyse further conversions obtaining finally a lighter brown colour DHICA-melanin.
  • melanin protects the body by absorbing ultraviolet radiation.
  • UV radiation causes sunburn along with other direct and indirect DNA damage to the skin, and the body naturally combats and seeks to repair the damage and protect the skin by creating and releasing further melanin into the skin's cells. With the production of the melanin, the skin color darkens. This process corresponds to the the tanning process.
  • MC1R has been known to be implicated in different UV-induced reaction such as pigmentation and adaptive tanning. UV-induced tans act as a photoprotection by providing a sun protection factor (SPF) of 3-4 and epidermal hyperplasia.
  • SPF sun protection factor
  • Graying of the hair is an important cause of low self-esteem, often interfering with socio-cultural adjustment.
  • the onset and progression of graying of the hair also designated as canities correlate very closely with chronological aging, and occur in varying degrees in all individuals eventually, regardless of gender or race.
  • Canities, such as premature canities may occur alone as an autosomal dominant condition or in association with various autoimmune or premature aging syndromes.
  • Reduction in melanogenically active melanocytes in the hair bulb of gray anagen hair follicles with resultant pigment loss is central to the pathogenesis of graying. Defective melanosomal transfers to cortical keratinocytes and melanin incontinence due to melanocyte degeneration are also believed to contribute to this.
  • hair dyes which are commonly used to dye grayed hair.
  • the use of such dyes is troublesome and sometimes causes side- effects such as rash of the scalp. Therefore, many users find hair dyes to be an unsatisfactory solution of the graying of the hair. Under such circumstances, it has been desired to develop a pharmaceutical preparation or a cosmetic composition for application to hair capable of essentially preventing graying of the hair and/or restoring grayed hair to its natural color.
  • the many types of skin pigmentation disorders may present in diverse forms and distributions and have various causes. They can be inherited (eg, vitiligo, familial periorbital hyperpigmentation), acquired (eg, postinflammatory pityriasis alba, idiopathic guttate hypomelanosis, Becker's nevus, melasma), infectious (eg, tinea versicolor), benign and self-limiting (eg, isolated cafe au lait spots, photocontact dermatitis), or a sign of more serious underlying disease (eg, multiple cafe au lait spots, malignant acanthosis nigricans).
  • vitiligo familial periorbital hyperpigmentation
  • acquired eg, postinflammatory pityriasis alba, idiopathic guttate hypomelanosis, Becker's nevus, melasma
  • infectious eg, tinea versicolor
  • benign and self-limiting eg, isolated cafe au la
  • pityriasis alba usually presents as ill defined, scaly patches of hypomelanosis on the cheeks of people with an atopic diathesis.
  • the face is also a favored site for vitiligo, but the distribution is periorificial, and the pigment loss is complete because of a destruction of melanocytes.
  • vitiligo is an autoimmune disease featuring a progressive loss of pigmentation of the skin. In vitiligo, this loss of pigmentation is directly correlated with a loss of melanocytes, resulting at the onset of the disease in white patches of different sizes appearing on different parts of the body.
  • Vitiligo affects both genders equally, although is a common observation that women complain earlier and more frequently about vitiligo, possibly because in some places vitiligo is considered as a stigma or a cosmetic problem.
  • the immune reaction can be mediated by cellular immunity, humoral antibody mediated immunity, and the action of cytokines.
  • Cell-mediated immunity in vitiligo is demonstrated by the presence of inflammatory infiltrates in perilesional vitiligo skin. Decreased CD4+ to CD8+ lymphocytes ratio in vitiligo-stricken skin compared to healthy skin and CD8 T cells directed against melanocytic antigens have been found both in perilesional skin and in the blood of vitiligo patients. This shows that the elimination of melanocytes by cytotoxic T cells is a mechanism leading to depigmentation in vitiligo.
  • Cytokines also seem to play an important role in vitiligo pathogenesis. There is an increase in the expression of tumour necrosis alpha (TNF-a) and interferon-gamma (IFN- ⁇ ), suggesting that vitiligo is mediated by a T helper cell-1 (Thl) response.
  • TNF-a tumour necrosis alpha
  • IFN- ⁇ interferon-gamma
  • IL- la Interleucin-l a
  • IL-6 Interleucin-6
  • oxidative stress is considered to be one of the possible pathogenic events in melanocyte loss.
  • the intracellular levels of H 2 0 2 and other reactive oxygen species (ROS) also increase in response to cytokines such as TNF-a and transforming growth factor ⁇ (TGF- ⁇ ), which are potent inhibitors of melanogenesis.
  • ROS reactive oxygen species
  • Depigmentation disease recovery depends on a viable melanocyte reservoir and in many patients with skin disease related to depigmentation, as vitiligo, repigmentation is possible when pigment cells are stimulated with appropriate topical or oral medications.
  • Melanocytes for repigmentation by medical methods arise from three main sources: (a) the hair follicle unit; (b) unaffected melanocytes within areas of depigmented epidermis, and (c) melanocytes located at the edge of skin depigmentation lesions. Most melanocytes originate from the hair follicle unit where they are present in large numbers and migrate towards the epidermis. A striking feature of the hair follicle reservoir is the enormous potential for providing pigment cells considering its tiny size and diameter.
  • hair follicles are absent on palms, soles, mucosal or semi-mucosal surfaces and therefore these areas become particularly refractory to all therapies because the melanocyte reservoir is lacking.
  • an essential need to treat skin disease related to depigmentation is to improve the migration of melanocyte to damaged skin area.
  • skin infection related to depigmentation causes little or no direct physical impairment, it is often considered just as a cosmetic problem.
  • the change in appearance caused by this skin disorder can affect a person's emotional and psychological well-being, having major consequences on his/her life.
  • skin infection related to depigmentation could be a long-lasting disease, and its unpredictable natural course causes a heavy burden on patients' quality of life (QoL).
  • melanocytes For repigmentation to occur, it is necessary that melanocytes become stimulated with appropriate signals.
  • two important properties of melanocytes have to be taken into consideration: (a) neo-melanogenesis, which implies melanin synthesis and production of melanosomes and b) melanocyte migration, which will help pigment cells to reach depigmented skin.
  • plant extract(s) and “vegetal extract(s)” are equally used to refer to a substance or an active with desirable properties that is removed from the tissue of a plant, usually by treating it with a solvent.
  • the present invention relates to a composition, advantageously a cosmetic composition, comprising a combination of vegetal extracts, from the plants Coleus forskohlii, Cassia occidentalis and/or Cassia alata.
  • compositions are disclosed for cosmeceuticals that aid in the retardation of the progression of canities or skin disease related to depigmentation such as vitiligo and/or at least partial repigmentation of the white patches. More specifically, the compositions herein disclosed are based on the use of a combination of active vegetal extracts, from the plants Coleus forskohlii, Cassia occidentalis and Cassia alata. These compositions are suitable for stimulating the survival, proliferation and differentiation of melanocytes, and activating melanogenesis. These active ingredients also possess antioxidant and antiinflammatory activities, may stimulate the cAMP pathway and increase the expression of MC 1R. In one aspect of the invention, the composition contains a cosmeceutically effective amount of both extracts of Coleus forskohlii, Cassia occidentalis and/or Cassia alata, in a cosmeceutically acceptable vehicle.
  • composition according to the invention is a topical composition comprising: a) a cosmeceutically acceptable vehicle ; b) an extract of Coleus forskohlii ; and c) an extract of Cassia occidentalis and/or Cassia alata.
  • the present invention is based on the discovery that the combination of vegetal extracts, namely Coleus forskohlii, Cassia occidentalis and/or Cassia alata, increases the number and activity of melanocytes in a more effective manner than each extract taken alone.
  • vegetal extracts namely Coleus forskohlii, Cassia occidentalis and/or Cassia alata
  • this combination of plant extracts in a cosmeceutically acceptable vehicle was an effective treatment for skin disease related to depigmentation, such as for example vitiligo, when applied topically on lesions of this disease.
  • Desired result may include to increasing the expression of Stem Cell Factor (SCF) and Basic Fibroblast Growth Factor (bFGF), and/or stimulating the conversion of melanoblasts to active melanocytes, and/or promoting the number of keratinocytes and stimulate their activity, and/or activating cAMP pathway and negatively reducing T-cell proliferation, and/or stimulating the Wnt/f3 catenin pathway, and/or reducing the levels of Transforming Growth Factor-beta (TGF- ⁇ ), and/or reducing the levels of interferon-gamma (IFN- ⁇ ), and/or reducing the levels of Tumour Necrosis Factor-alpha (TNF-a), and/or reducing the levels of various proinflammatory cytokines, especially IL-la and IL-6, and/or reducing the levels of oxidative stress, and/or inhibiting Nitric Oxide Synthase (NOS) and nitric oxide (NO) production, and/or increasing the expression of MC I R,
  • compositions that bring out the desired result.
  • the composition according to the invention further comprises a penetration enhancer, advantageously a skin penetration enhancer.
  • the extract of Coleus forskohlii is a root extract, advantageously an ethanol/propylene glycol root extract ;
  • the extract of Cassia occidentalis is a pod extract, advantageously a pod methanolic extract ;
  • the extract of Cassia alata is a leave extract, advantageously a methanolic leave extract.
  • the Coleus forskohlii extract represents between 0.01 and 15.0% in weight of the composition, advantageously between 0.1 and 10.0%, preferably between 5.0 and 8.0%.
  • the Cassia occidentalis or Cassia alata extract represents between 0.01 and 10.0% in weight of the composition, advantageously between 0.1 and 8.0%, preferably between 2.0 and 5.0%.
  • the weight ratio of Coleus forskohlii extract: Cassia occidentalis and/or Cassia alata represents 3 : 1.
  • the penetration enhancer is diethylene glycol monoethyl ether and represents between 0.5 and 5.0% in weight of the composition, advantageously between 1.0 to 2.0 %.
  • the pH of the composition according to the invention is between 6.5 to 7.1.
  • the composition has a specific pH of 6.8 which appears to be the most convenient value for the melanosomes activity.
  • the composition contains a buffer which permits to reach a pH as close as possible to 6.8
  • the composition contains a cosmeceutically acceptable preservative.
  • the composition is a leave-on product or a rinse-off product.
  • composition above described is for therapeutic or non-therapeutic use to promote the proliferation of melanocytes in the skin and/or in the hair follicle unit.
  • the composition is for therapeutic or non-therapeutic use to promote the melanogenesis in the skin and/or in the hair follicle unit.
  • the composition is for therapeutic or non-therapeutic use to treat canitie.
  • the composition above described is for therapeutic or non-therapeutic use as a tanning agent.
  • the composition according to the invention is for therapeutic or non-therapeutic use to treat skin disease related to depigmentation in a human subject.
  • the skin disease related to depigmentation is selected from the group consisting of pytiriasis alba, pytiriasis versicolor, idiopathic guttate hypomelanosis, progressive macular hypomelanosis, post-inflammatory hypopigmentation and vitiligo.
  • the skin disease related to depigmentation is vitiligo.
  • the composition contains a cosmeceutically effective amount of a combination of an extract of Coleus forskohlii, an extract of Cassia occidentalis and/or an extract of Cassia alata, a penetration enhancer, a buffer and a preservative in a cosmeceutically acceptable medium.
  • the composition according to the invention containing a cosmeceutically effective amount of a combination of an extract of Coleus forskohlii, an extract of Cassia occidentalis and/or an extract of Cassia alata, a penetration enhancer, a buffer and a preservative in a cosmeceutically acceptable medium is topically applied.
  • the composition according to the invention contains a cosmeceutically effective amount of a combination of an extract of Coleus forskohlii, an extract of Cassia occidentalis and/or an extract of Cassia alata, a penetration enhancer , a buffer and a preservative in a cosmeceutically acceptable medium treats skin disease related to depigmentation , advantageously selected from the group consisting of pytiriasis alba, pytiriasis versicolor, idiopathic guttate hypomelanosis, progressive macular hypomelanosis, post-inflammatory hypopigmentation and vitiligo, preferably vitiligo.
  • the composition acts to increase the expression of Stem Cell Factor (SCF) and Basic Fibroblast Growth Factor (bFGF).
  • SCF Stem Cell Factor
  • bFGF Basic Fibroblast Growth Factor
  • the composition acts to stimulate the conversion of melanoblasts to active melanocytes and hence promote the proliferation of melanocytes.
  • the composition acts to promote the number of keratinocytes and stimulate their activity.
  • the composition acts to activate cAMP pathway and negatively reduce T-cell proliferation. In another aspect, the composition acts to stimulate the Wnt/B catenin pathway.
  • composition acts to reduce the levels of Transforming Growth Factor-beta (TGF- ⁇ ).
  • TGF- ⁇ Transforming Growth Factor-beta
  • the composition acts to reduce the levels of interferon-gamma (IFN- ⁇ ). In another aspect, the composition acts to reduce the levels of Tumour Necrosis Factor-alpha (TNF-a).
  • IFN- ⁇ interferon-gamma
  • TNF-a Tumour Necrosis Factor-alpha
  • the composition acts to reduce the levels of various proinflammatory cytokines, especially IL-la and IL-6.
  • the composition acts to reduce the levels of oxidative stress. In another aspect, the composition acts to inhibit Nitric Oxide Synthase (NOS) and nitric oxide (NO) production.
  • NOS Nitric Oxide Synthase
  • NO nitric oxide
  • composition acts to increase the expression of MC1R.
  • the composition acts to restore the physiological levels of Microphtalmia Transcription Factor (Mitf).
  • Coleus forskohlii extracts increase the expression of Stem Cell Factor (SCF) and Basic Fibroblast Growth Factor (bFGF).
  • SCF Stem Cell Factor
  • bFGF Basic Fibroblast Growth Factor
  • Cassia occidentalis and/or Cassia alata extracts may stimulate the conversion of melanoblasts to active melanocytes.
  • the Applicant has discovered that the combination of Coleus forskohlii extract and Cassia occidentalis extract may promote melanogenesis in a more important manner than each active ingredient taken separately. In other words, the plant extracts act synergetically.
  • a composition of the present invention contains from about 5.0 to 8.0 % in weight of the composition of a Coleus forskohlii extract (ethanol/propylene glycol root extract), about 2.0 to 5.0 % in weight of the composition of a Cassia occidentalis extract (pod methanolic extract) and/or of a Cassia alata extract (leave methanolic extract), about 1.0 to 2.0 % in weight of the composition of a penetration enhancer in a buffer solution bringing the composition pH between 6.5 to 7.1, advantageously as close as possible to a value of 6.8, preferably the pH value is 6.8.
  • the invention concerns a method of treating skin infection related to depigmentation by topical application to a subject of the composition as above defined.
  • composition of the invention may also be therapeutically or non-therapeutically used in hypomelanotic disorders such as post inflammatory hypomelanosis, infectious or parasitic hypomelanosis (e.g. Pityriasis (Tinea) Versicolor, Leprosy, Treponematoses, Onchocerciasis, Postkala-azar Dermatosis, Herpes Zoster), Halo Nevus, Melanoma associated leukoderma, hypomelanosis from physical agents, hypomelanosis from chemical or pharmacological agents, hypomelanosis of Ito, nevus depigmentosus, Hypopigmented Mycosis Fungoides, Scleroderma and Lichen Sclerosus associated hypomelanosis, Lupus Erythematosus associated hypomelanosis, sarcoidosis associated hypomelanosis and Pityriasis Alba.
  • infectious or parasitic hypomelanosis e.g. Pityriasis (Tinea) Versicolor
  • the present invention refers to a composition comprising a cosmeceutically acceptable vehicle.
  • a cosmeceutically acceptable vehicle comprises ingredients commonly used in skin care products such as water, liquid or solid emollients, silicone oils, emulsifiers, solvents, humectants, thickeners and so on.
  • Other ingredients which can be used in the vehicle include penetration enhancers, buffers, preservative agents or moisturizing agents or combinations thereof.
  • a cosmeceutically acceptable vehicle suitable for use in the present invention comprises water, propylene glycol dipelargonate, propylene glycol, stearic acid, mineral (paraffinum liquidum) oil, glyceryl stearate, PEG-75 stearate, glycol stearate, cetyl palmitate, avocado (Persea gratissima) oil, triethanolamine, magnesium aluminum silicate, cellulose gum, petrolatum, methylparaben, sorbic acid, xanthan gum.
  • a cosmeceutically acceptable vehicle comprises water, caprylic/capric triglyceride, glycerine, propylene glycol, decyl oleate, dicaprylyl carbonate, glyceryl stearate, cetearyl alcohol, stearic acid, cetearyl glucoside, xanthan gum, locust bean (Ceratonia siliqua) gum, sodium hydroxide.
  • the cosmeceutically acceptable vehicle may also consist of water, propylene glycol, carbomer, xanthan gum, sorbic acid, disodium EDTA, sodium hydroxide.
  • Other ingredients which may also be used as cosmeceutically acceptable vehicle are water, propylene glycol, carbomer, acrylates/ClO-30 alkyl acrylate crosspolymer, sodium hydroxide.
  • the present invention comprises a cosmeceutically effective amount of Coleus forskohlii extract.
  • the term "cosmeceutically acceptable amount” refers to an amount of Coleus forskohlii extract necessary to achieve a desired result.
  • the cosmeceutically effective amount of Coleus forskohlii extract is dependent on the number of active cells, or area of the skin to be treated.
  • a composition of the present invention comprises from about 0.01 to 15.0 weight percent Coleus forskohlii extract, from about 0.1 to 10.0 weight percent Coleus forskohlii extract, or about 5 to 8.0 weight percent Coleus forskohlii extract.
  • the composition comprises a cosmeceutically effective amount of Cassia occidentalis extract.
  • the term “cosmeceutically acceptable amount” refers to an amount of Cassia occidentalis extract necessary to achieve a desired result.
  • the composition can be formulated into a number of acceptable forms.
  • a skin care composition can be formulated as aqueous solution, a water-in-oil (w/o) emulsion, an oil-in-water (o/w) emulsion, a dispersion of lipids, an aqueous, water- alcohol, oil or oil-alcohol gel.
  • the cosmeceutically acceptable vehicle itself is an (w/o) or (o/w) emulsion, it can contain from about 1 to about 50% of an oil phase and from about 35 to about 95% water, with respect to the weight of the whole composition.
  • the topical composition may be prepared.
  • the active components are generally incorporated in a cosmeceutically acceptable carrier in a conventional manner.
  • the active components can suitably be dissolved or dispersed in a portion of the water or another solvent or liquid to be incorporated in the composition.
  • the composition may be in the form of conventional skin-care products such as a cream, gel, lotion or the like.
  • the compositions of the present invention can be formulated as a "leave-on" product, i.e., a product to be applied to the skin without a deliberate rinsing step after its application to the skin.
  • the composition may be packaged in any suitable manner such as in a jar, a bottle, an airless bottle or a tube.
  • compositions described in the present invention may be applied one or more times daily to the portion of skin requiring treatment.
  • the present invention comprises topically applying a composition of the present invention one or more times daily for a period of about 1 to 36 weeks, and beyond.
  • the product is intended to be used long-term.
  • a quantity of about 0.25mg/cm 2 of a composition of the present invention is applied topically to the skin, spread over and/or rubbed into the skin using the hands or fingers.
  • the present invention is directed to a method of treating vitiligo and any over kind of hypopigmentation comprising the step of topically administering to a subject in need thereof, a composition comprising a cosmeceutically acceptable vehicle and a cosmeceutically effective amount of a combination of Coleus forskohlii extract, Cassia occidentalis extract and/or Cassia alata extract.
  • FIGURES Figure 1 depicts human melanocytes cultured during 96 hours with AJ Control (NaCI 0.9% solution) B/ Cassia occidentalis extract (5 ⁇ g/ml) CI Coleus forskohlii extract (5 ⁇ g /ml) and D/ Coleus forskohlii extract (5 ⁇ g /ml) + Cassia occidentalis extract (5 ⁇ g /ml).
  • Figure 2 depicts melanin contents of BC16 melanoma murine cells treated during 96 hours in presence of control (NaCI 0.9% solution), Coleus forskohlii extract (C. forskohlii ; 5 ⁇ g /ml) ; Cassia occidentalis extract (C. occidentalis ; 5 ⁇ g /ml) ; Cassia alata extract (C.
  • FIG 3 depicts the values of Microphthalmia-associated transcription factor (Mitf), Tyrosinase-related protein- 1 (TRP-1), Tyrosinase-related protein-2 (TRP-2) and Tyrosinase (TYR) in A375 melanocytes after 96 hours in culture with control (NaCI 0.9%), Cassia occidentalis extract (5 ⁇ g /ml), Coleus forskohlii extract (5 ⁇ g /m l) and combination of Cassia occidentalis extract (5 ⁇ g /ml) and Coleus forskohlii (5 ⁇ g /ml).
  • Mitf Microphthalmia-associated transcription factor
  • TRP-1 Tyrosinase-related protein- 1
  • TRP-2 Tyrosinase-related protein-2
  • TRP-2 Tyrosinase
  • Figure 4 depicts the levels of Transforming Growth Factor- ⁇ in skin biopsies of normal skin and lesional skin of vitiligo patients, and after treatment of the lesional melanocytes with Cassia occidentalis extract (5 ⁇ g /m l), Coleus forskohlii extract (5 ⁇ g /ml), and the combination of both Cassia occidentalis extract (5 ⁇ g /ml) and Coleus forskohlii extract (5 ⁇ g /ml).
  • Figure 5 depicts the levels of Tumour Necrosis Factor-a in skin biopsies of normal skin and lesional skin of vitiligo patients, and after treatment of the lesional melanocytes with Cassia occidentalis extract (5 ⁇ g /m l), Coleus forskohlii extract (5 ⁇ g /ml), and the combination of both Cassia occidentalis extract (5 ⁇ g /ml) and Coleus forskohlii extract (5 ⁇ g /ml).
  • Figure 6 depicts the levels of Interferon- ⁇ in skin biopsies of normal skin and lesional skin of vitiligo patients, and after treatment of the lesional melanocytes with Cassia occidentalis extract (5 ⁇ g /ml), Coleus forskohlii extract (5 ⁇ g /ml), and the combination of both Cassia occidentalis extract (5 ⁇ g /ml) and Coleus forskohlii extract (5 ⁇ g /ml).
  • Figures 7 to 10 depict a subject with vitiligo before ( Figures 7 and 9) and after ( Figures 8 and 10) topical treatment with a composition of the present invention during 30 days.
  • compositions on the skin of patients afflicted by skin disease related to depigmentation such as vitiligo, (for example once a day, or two daily applications) has shown response featuring the reduction of depigmentation and reduction in the progression of disease, and even partial repigmentation of white patches.
  • skin disease related to depigmentation such as vitiligo
  • the use of the combination of these two vegetal active extracts under a cosmeceutically acceptable form stimulates the survival, proliferation and differentiation of melanocytes.
  • Example 1 Effect of the composition according to the invention comprising Coleus forskohlii extract and Cassia occidentalis extract or Cassia alata extract on melanocytes proliferation
  • Figure 1 depicts culture of human melanocytes treated with control, with each of the extracts, and with the combination of both extracts for 96 hours.
  • Coleus forskohlii extract and Cassia occidentalis extract show increased melanocyte proliferation
  • combination of Coleus forskohlii extract and Cassia occidentalis extract show increased melanocyte proliferation, more important than with each active ingredient taken separately.
  • Example 2 Effect of the composition according to the invention comprising Coleus forskohlii extract and Cassia occidentalis extract on melanogenesis
  • Figure 2 depicts melanogenesis in B 16 melanoma murine melanocytes treated with control, with Coleus forskohlii extract , with Cassia occidentalis extract, with Cassia alata extract and with the combination of Coleus forskohlii extract + Cassia occidentalis extract or Coleus forskohlii extract + Cassia alata extract, ⁇ diethylene glycol monoethyl ether. It is obvious that the combination of Coleus forskholii with Cassia occidentalis or Cassia alata stimulates melanogenesis in a more important manner than each extract taken separately, compared with control.
  • Melanogenesis is a complex biological process where eumelanin and phaeomelanin derive from a common tyrosinase-dependent pathway with the same precursor, tyrosine. From dopaquinone, the eumelanin and phaeomelanin pathways diverge.
  • Two enzymes crucial to eumelanogenesis are the tyrosinase-related proteins TRP1 (also known as GP75 or b-locus) and TRP2 (also known as dopachrome tautomerase, DCT).
  • TRP1 also known as GP75 or b-locus
  • TRP2 also known as dopachrome tautomerase, DCT.
  • Mitf Microphthalmia-associated transcription factor
  • Example 4 Effect of the composition according to the invention comprising Coleus forskohlii extract and Cassia occidentalis extract on the expression of TGF- ⁇
  • Example 5 Effect of the composition according to the invention comprising Coleus forskohlii extract and Cassia occidentalis extract on the expression of TNF-a
  • TNF-a levels of TNF-a were also shown to be increased in skin biopsies of vitiligo lesions compared to normal skin. Cases of refractory generalized vitiligo showed high tissue levels of TNF-a. Considering these cases, patients with a strong TNF-a staining were characterized by a higher vitiligo disease activity score than patients with a weak staining, which suggests a probable role of TNF-a in the pathogenesis of vitiligo. A study revealed significant increase in TNF-a transcript and protein levels in vitiligo patients compared to controls.
  • TNF-a can inhibit melanogenesis by decreasing the intracellular levels of tyrosinase and tyrosinase-related protein 1, involved in both melanogenesis and prevention of melanocyte death.
  • TNF-a -treated melanocytes show marked cellular shrinking and reduced melanin production in vitro, as well as downregulation of Mitf, a transcription factor essential in the regulation of melanocyte development, proliferation, death, and melanogenesis.
  • the Applicant have been able to confirm higher levels of TNF-a in biopsies taken from lesional skin of vitiligo patients, compared to normal skin of the same patients. Further, treating these explants with Cassia occidentalis extract, these levels of TNF-a were slightly decreased. The reduction was much more important when treated with Coleus forskohiii extract, and unexpectedly the Applicant discovered that treatment with the combination of Cassia occidentalis extract and Coleus forskohiii extract was leading to a decrease in TNF-a much more substantial than the decrease observed with each of these extracts taken separately.
  • Example 6 Effect of the composition according to the invention comprising Coleus forskohlii extract and Cassia occidentalis extract on the expression of IFN- ⁇
  • IFN- ⁇ cytokine interferon- ⁇
  • the Applicant have also demonstrated in skin explants from lesional skin of vitiligo patients increased levels of IFN- ⁇ compared with normal skin of the same patients. As depicted in Figure 6, treating these explants with Cassia occidentalis extract leaded to a decrease in the level of IFN- ⁇ more or less similar to that produced by treatment with Coleus forskohiii extract. Unexpectedly the Applicant found that the association of both extracts leaded to a higher reduction of IFN- ⁇ levels.
  • Example 7 Effect of the composition according to the invention comprising Coleus forskohiii extract and Cassia occidentalis extract to treat vitiligo
  • Figures 7 to 10 depict the results of increased melanogenesis and melanocyte proliferation four weeks after topical application once a day of the composition of the invention to two subj ects with vitiligo.
  • vitiligo with a composition comprising a combination of Coleus forskohiii extract, Cassia occidentalis extract and/or Cassia alata extract in a cosmeceutically acceptable vehicle containing also a penetration enhancer, and whose pH is maintained as close as possible to 6.8 was found to be successful.
  • This composition is an oil-in-water emulsion, the colour is beige, it is smooth, unctuous, semi-liquid and its pH is ranging from 6.5 to 7.1 Its odour is sui generi.
  • This preparation is stable over time and may be applied on the skin once or twice daily during an unlimited period of time. One can observe, sometimes as soon as ten days, more generally in the course of the month following its application, a limitation and even a stop in depigmentation and usually a visible repigmentation as seen in Figures 7 to 10. Further applying this emulsion prevents further depigmentation.
  • Example 1 is repeated incorporating in the emulsion solely Coleus forskohlii extract. The effect is more limited and appears after a longer time.
  • Example 1 is repeated without adjusting the pH between 6.5 to 7.1, but with a pH value more acidic, i.e. between 5.5 and 6.5.
  • the emulsion obtained has a pretty similar appearance and the same physical properties than in example 1 (except for its pH). However, a limitation of depigmentation is observed in a slower and more sporadic manner than in example 1.
  • Example 1 is repeated replacing the vegetal extracts of Coleus forskohlii and Cassia occidentalis by other vegetal extracts. No result is observed.

Abstract

Une composition topique comprenant : a) un véhicule cosmétiquement acceptable; b) un extrait de Coleus forskohlii; et c) un extrait de Cassia occidentalis et/ou Cassia alata.
PCT/IB2018/055248 2017-07-14 2018-07-16 Composition cosmétique comprenant coleus forskohlii et cassia occidentalis et/ou cassia alata, et compositions destinées à être utilisées dans le traitement du vitiligo WO2019012513A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2020523837A JP2020527604A (ja) 2017-07-14 2018-07-16 コレウス・フォルスコリ、およびカッシア・オクシデンタリスおよび／またはカッシア・アラタを含む化粧品組成物、ならびに白斑の治療における使用
US16/630,904 US20200155634A1 (en) 2017-07-14 2018-07-16 Cosmetic composition comprising coleus forskohlii and cassia occidentalis and/or cassia alata, and compositions for use in treating vitiligo
EP18750507.8A EP3651861A1 (fr) 2017-07-14 2018-07-16 Composition cosmétique comprenantcoleus forskohlii

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IBPCT/IB2017/054256 2017-07-14
IBPCT/IB2017/054256 2017-07-14

Publications (1)

Publication Number Publication Date
WO2019012513A1 true WO2019012513A1 (fr) 2019-01-17

Family

ID=60191421

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/055248 WO2019012513A1 (fr) 2017-07-14 2018-07-16 Composition cosmétique comprenant coleus forskohlii et cassia occidentalis et/ou cassia alata, et compositions destinées à être utilisées dans le traitement du vitiligo

Country Status (4)

Country Link
US (1) US20200155634A1 (fr)
EP (1) EP3651861A1 (fr)
JP (1) JP2020527604A (fr)
WO (1) WO2019012513A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220010101A (ko) * 2020-07-17 2022-01-25 양승원 오수유열매와 콜레우스 포스콜리 복합 추출물을 함유하는 탈모방지 및 흰머리 억제 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006037188A1 (fr) * 2004-10-08 2006-04-13 Clinuvel Pharmaceuticals Limited Préparations et méthodes permettant d’induire la mélanogenèse chez un sujet
US20080226571A1 (en) * 2007-03-16 2008-09-18 Muhammed Majeed Compositions and methods to effect enhanced photoprotection against UV A and UV B induced damage of human skin
WO2010019450A2 (fr) * 2008-08-09 2010-02-18 Nyles Bauer Composés actifs synergiques pour traiter une inflammation et d'autres états
KR20110008609A (ko) * 2009-07-20 2011-01-27 인하대학교 산학협력단 석결명 추출물을 유효성분으로 함유하는 백반증 치료용 약학적 조성물
WO2015195894A1 (fr) * 2014-06-18 2015-12-23 The General Hospital Corporation Méthodes et compositions pour moduler les niveaux de bêta-endorphine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2650952B1 (fr) * 1989-08-17 1994-10-14 Lvmh Rech Composition cosmetique ou pharmaceutique, notamment dermatologique, contenant un extrait de coleus et procede pour sa preparation
JPH03188024A (ja) * 1989-12-15 1991-08-16 Pola Chem Ind Inc 皮膚外用剤
KR20110008610A (ko) * 2009-07-20 2011-01-27 인하대학교 산학협력단 카시아 알라타 추출물을 유효성분으로 함유하는 백반증 치료용 약학적 조성물
JP5836666B2 (ja) * 2011-06-28 2015-12-24 日華化学株式会社 Ｍｉｔｆ−ｍ産生促進剤、及び該ｍｉｔｆ−ｍ産生促進剤を含有する毛髪用化粧料組成物並びに皮膚用化粧料組成物
WO2015121102A1 (fr) * 2014-02-13 2015-08-20 Basf Se Ester éthylique de capryloylalanine en tant qu'activateur de pénétration

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006037188A1 (fr) * 2004-10-08 2006-04-13 Clinuvel Pharmaceuticals Limited Préparations et méthodes permettant d’induire la mélanogenèse chez un sujet
US20080226571A1 (en) * 2007-03-16 2008-09-18 Muhammed Majeed Compositions and methods to effect enhanced photoprotection against UV A and UV B induced damage of human skin
WO2010019450A2 (fr) * 2008-08-09 2010-02-18 Nyles Bauer Composés actifs synergiques pour traiter une inflammation et d'autres états
KR20110008609A (ko) * 2009-07-20 2011-01-27 인하대학교 산학협력단 석결명 추출물을 유효성분으로 함유하는 백반증 치료용 약학적 조성물
WO2015195894A1 (fr) * 2014-06-18 2015-12-23 The General Hospital Corporation Méthodes et compositions pour moduler les niveaux de bêta-endorphine

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220010101A (ko) * 2020-07-17 2022-01-25 양승원 오수유열매와 콜레우스 포스콜리 복합 추출물을 함유하는 탈모방지 및 흰머리 억제 조성물
KR102444089B1 (ko) * 2020-07-17 2022-09-16 양승원 오수유열매와 콜레우스 포스콜리 복합 추출물을 함유하는 탈모방지 및 흰머리 억제 조성물

Also Published As

Publication number Publication date
JP2020527604A (ja) 2020-09-10
EP3651861A1 (fr) 2020-05-20
US20200155634A1 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
KR101550917B1 (ko) 인삼씨 추출물을 함유하는 피부 외용제 조성물
KR101707522B1 (ko) 인삼 꽃 추출물을 함유하는 피부 외용제 조성물
KR101339096B1 (ko) 과색소침착 피부용 피부 미백 조성물
CA2793555A1 (fr) Composition contenant de l'extrait de dionee attrape-mouches, pour traitement cosmetique
RU2571691C2 (en) Method of treatment of cellulite
US9168279B2 (en) Compositions comprising paulownin and/or Paulownia extracts and uses thereof
JP4921732B2 (ja) メラニン合成促進剤及び皮膚外用剤
US20200155634A1 (en) Cosmetic composition comprising coleus forskohlii and cassia occidentalis and/or cassia alata, and compositions for use in treating vitiligo
KR20140081138A (ko) 우장지버섯 자실체 추출물 또는 우장지버섯 균사체 추출물을 함유하는 피부 외용제 조성물
US9173913B2 (en) Compositions comprising Paulownia tomentosa wood extracts and uses thereof
KR101156968B1 (ko) 멜라노사이트의 수상돌기 신장 억제제 및 이를 함유하는 피부 외용제
KR101458496B1 (ko) 아위버섯 자실체 추출물 또는 아위버섯 균사체 추출물 또는 아위버섯 균사체 배양액을 함유하는 항염용 피부 외용제 조성물
KR20140081137A (ko) 곰보버섯 자실체 추출물 또는 곰보버섯 균사체 추출물을 함유하는 피부 외용제 조성물
US9962326B2 (en) Compositions comprising paulownia tomentosa wood extracts and uses thereof
KR101156970B1 (ko) 멜라노사이트의 수상돌기 신장 억제제 및 이를 함유하는피부 외용제
CN112007039A (zh) 一种包含氟西汀和维生素d3或其衍生物的组合物，及其应用
TWI605832B (zh) Plant extract composition for desalinating skin and reducing melanin, pharmaceuticals and uses thereof
KR101138811B1 (ko) 버들송이 추출물을 함유하는 피부 외용제 조성물
KR100561781B1 (ko) 방기 추출물을 유효성분으로 함유하는 피부 미백용 조성물
US9168219B2 (en) Compositions comprising Paulownia tomentosa wood extracts and uses thereof
KR20160028032A (ko) 파극천 고온고압 추출물을 함유하는 피부외용제 조성물
ES2379768T3 (es) Composición cosmética adelgazante que contiene una sustancia inductora de la producción de IL-6
KR20160132151A (ko) 피부 외용제 조성물
CN113425651A (zh) 一种具有美白功效的化妆品组合物及其应用
JP2000169497A (ja) 新規なトリテルペン類およびこれを含有する組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18750507

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020523837

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018750507

Country of ref document: EP

Effective date: 20200214